<allTrials totalCount="44" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-05T00:00:00.000Z">19709160</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Analyses of PAThogen and HOSt determinants in hospitalised patients with a laboratory confirmed infection caused by Staphylococcus aureus: the PATHOS study</title>
      <scientificTitle/>
      <acronym>PATHOS study</acronym>
      <studyHypothesis>To identify candidate antigens for the development of a prophylactic Staphylococcus aureus vaccine by studying expression profiles of host and pathogen determinants during natural infection.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Putative antigen targets for the development of a Staphylococcus aureus vaccine.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19709160</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, non-randomised, non-controlled, single armed clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4efae4cd-8d58-4209-ac05-dea2340bb5fe">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients (greater than 18 years) with S. aureus bacteraemia or wound infection
2. Diagnosis of S. aureus infection within 48 hours after initial cultures
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Incapacitated patients (Glasgow Coma Scale [GSC] less than 15)
2. Patients with neutropenia (less than 500x 10^6 neutrophils/L)
3. Patients with haematological malignancy
4. Transplantation patients
5. Patients who are treated with immunosuppressive drugs</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Staphylococcus aureus infection and vaccination</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Blood will be drawn at days 2, 7 and 14 after the moment that the initial blood and wound cultures were obtained. This will be done simultaneously to drawing blood for routine haematology and chemistry investigations according good clinical practice, so no extra venapuncture is required for participation in the study. At day 2 two nasal swabs will be obtained for assessment of Staphylococcus aureus nasal carriage.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16901-0</funderId>
      <contactId>Contact54860_16901</contactId>
      <sponsorId>Sponsor53418</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54860_16901">
    <title>Prof</title>
    <forename>J.A.J.W. </forename>
    <surname>Kluytmans</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
Department of Medical Microbiology and Infection Control
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 0552</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.kluytmans@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53418">
    <organisation>Wyeth Pharmaceuticals B.V. (The Netherlands)</organisation>
    <website>http://www.wyeth.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 255</address>
      <city>Hoofddorp</city>
      <country>Netherlands</country>
      <zip>2130 AG  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)23 567 2567</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info-nl@wyeth.com </email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487416.8</gridId>
    <rorId>https://ror.org/02bzf1224</rorId>
  </sponsor>
  <funder id="Funder16901-0">
    <name>Wyeth Pharmaceuticals B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-09-05T00:00:00.000Z">45091963</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Preventing early language delay: a pilot study</title>
      <scientificTitle/>
      <acronym>LLL (Let's Learn Language)</acronym>
      <studyHypothesis>To determine the feasibility of conducting a randomised controlled trial investigating a preventative approach to improve children's language development and behaviour problems at two years of age. Aims of this pilot were to:
1. Examine whether families whose children score at or below the 20th percentile on a standardised vocabulary measure agree to be randomised to a six-week Parent Language Program and to a non-intervention group
2. Compare the usefulness of two standardised vocabulary measures for post-test assessment: the SureStart 100 word Vocabulary Checklist (adapted from the MacArthur Bates Communicative Development Inventories [MBCDI] by Roy, Kersley and Law [2005]) or the Vocabulary Checklist from the complete MBCDI (approx 680 words divided into semantic categories)
3. Trial the videotaping of post-test assessment at 21 - 24 months
4. Solicit parents' evaluations of the program's content and format to provide information about program changes that may increase the feasibility of the Parent Language Program for families in Victoria

This is the pilot study to the randomised trial assigned to ISRCTN20953675.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes are to pilot and refine: 
1. Parent interest in, and attendance at, a six-week parent language promotion program 
2. Organisation and format of the Parent Language Program sessions, adapted from You Make The Differenceâ„¢ program
3. The sensitivity of the assessment tools used during the follow-up</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite>http://www.rch.org.au/emplibrary/ccch/TheLetsLearnLanguage.pdf</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received ethics approval from The Royal Children's Hospital Ethics in Humans Research Committee (EHRC) on the 7th June 2007 (ref: 26073A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45091963</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pilot randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b375517e-4400-4ab2-9456-99848c2decb8">
	  <name>Royal Children's Hospital</name>
	  <address/>
	  <city>Melbourne</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3052</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents of 18 - 21 month-old toddlers 
2. Attending any of eight well-child clinics within one Melbourne local government area
3. Identified by a brief, parent-reported vocabulary questionnaire as having minimal or no expressive vocabulary (e.g., scoring at or below the 20th percentile relative to age and sex norms)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Target sample size was 100 to identify 20 eligible children. Recruitment status achieved was 103, which identified 30 eligible children.</totalTarget>
      <exclusion>1. Children with already-diagnosed (or a referral for) cognitive delay or major medical conditions
2. Children with symptoms of Autism Spectrum Disorder
3. Parents with insufficient English to attend a parent language program and complete brief written questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Early delay in acquiring expressive vocabulary</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Vocabulary disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For each pair of eligible families recruited, one was randomly allocated to the Parent Language Program Group and one to the Usual Care Group. Masking occurred at randomisation, with group allocation concealed from the principal researcher and participants until allocation was complete. Group allocation was concealed from the researcher conducting follow-up direct assessments with intervention (Parent Language Program) families until data collection was complete.  

Arm A - Parent Language Program Group: 
A six-week parent language promotion program (six two-hour group sessions) adapted from the Hanen You Make The Differenceâ„¢ program, offered to parents when children were 19 - 22 months old. The Parent Language Program teaches child-centred, interaction-promoting and language-modelling responsive interaction strategies targeting the development of vocabulary and multi-word phrases. The Parent Language Program was conducted within the family's local community, facilitated by an early childhood professional.

Arm B - Usual Care Group:
Usual care from the Maternal and Child Health (MCH) nurses who provide a universal and free surveillance service to Melbourne families in the first five years of life (active control).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16684-0</funderId>
      <contactId>Contact54642_16684</contactId>
      <sponsorId>Sponsor53197</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54642_16684">
    <title>Dr</title>
    <forename>Melissa </forename>
    <surname>Wake</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Children's Hospital
Flemington Road
Parkville</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3052</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9345 5761</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.wake@rch.org.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53197">
    <organisation>Murdoch Childrens Research Institute, Parkville (Australia)</organisation>
    <website>http://www.rch.org.au/rch/index.cfm?doc_id=1495</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Associate Professor Melissa Wake
Royal Children's Hospital
Flemington Road
Parkville</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3052</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9345 5761</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.wake@rch.org.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1058.c</gridId>
    <rorId>https://ror.org/048fyec77</rorId>
  </sponsor>
  <funder id="Funder16684-0">
    <name>Murdoch Childrens Research Institute, Parkville (Australia)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-09-03T00:00:00.000Z">07857866</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The  Effectiveness of Acupuncture for Insomnia</title>
      <scientificTitle/>
      <acronym>EAI</acronym>
      <studyHypothesis>Traditional Chinese Medicine (TCM) Meridian Theory.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pittsburgh Sleep Quality Index (PSQI) records (PSQI assessment will be carried out on a weekly basis).</primaryOutcome>
      <secondaryOutcome>Serious adverse events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Review Board at Taipei City Hospital (IRB/TCH) (ref: 960302)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07857866</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>096XDAA00028</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="995a6e0b-892b-4f97-a103-2ba3934d61e9">
	  <name>145 Zhengzhou Road</name>
	  <address/>
	  <city>Taipei City</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>10341</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants suffering from insomnia who have not taken any sleep medications associated with psychiatric disorders within 30 days.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Pregnancy 
2&#129;. Central nervous system disease such as seizure disorder, cerebrovascular disease, dementia etc.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Insomnia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Acupuncture 
2. StilnoxÂ® (non-benzodiazepines) 5 mg/day at bedtime (hs) for 4 weeks</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16826-0</funderId>
      <contactId>Contact54784_16826</contactId>
      <sponsorId>Sponsor53340</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54784_16826">
    <title>Dr</title>
    <forename>Yu-Yang </forename>
    <surname>Chiang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>145 Zhengzhou Road
Datong District</address>
      <city>Taipei City</city>
      <country>Taiwan</country>
      <zip>10341</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 2 25523234 ext 5207</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chiang3940@yahoo.com.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53340">
    <organisation>Taipei City Hospital (Taiwan)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>145 Zhengzhou Road
Datong District</address>
      <city>Taipei City</city>
      <country>Taiwan</country>
      <zip>10341</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 2 25523234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chiang3940@yahoo.com.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410769.d</gridId>
    <rorId>https://ror.org/02gzfb532</rorId>
  </sponsor>
  <funder id="Funder16826-0">
    <name>Taipei City Government (Taiwan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-09-03T00:00:00.000Z">82127342</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic control of hospitalized diabetes mellitus patients: Application of standardised insulin protocols to hospitalized diabetes mellitus patients</title>
      <scientificTitle/>
      <acronym>COMETADIH</acronym>
      <studyHypothesis>Type 2 Diabetes Mellitus (DM2) is the leading cause of death and the most common diagnosis in hospitalized patients in Mexico. The economic burden that DM2 imposes to the public health system is onerous. Strategies focused on improving medical care and optimising resources are of paramount importance.

In-patient hyperglycemia negatively affects related comorbidities and has been linked to negative outcomes when compared to strategies that attain good glycemic control. Traditional insulin sliding scales are still widely used to treat in-patient hyperglycemia, even though this approach has been questioned and at present time is not considered good clinical practice. Novel strategies must be explored and compared to traditional insulin sliding scales.

Hypothesis of this study: Glycemic control of in-patients can be improved by the implementation of standardised insulin protocols. Glycemic control achieved by standardised insulin protocols will be better compared to traditional insulin sliding scales.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean CBG during study period 
2. Mean VBG during study period
3. Hypoglycemic episodes</primaryOutcome>
      <secondaryOutcome>1. Clinical condition at the end of study period
2. Health team acceptance and adherence to the protocol guidelines
3. In-hospital morbidity and mortality registered during hospitalization</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Human Biomedical Research Institutional Committee (an internal regulatory organisation for clinical research and ethics) approved this trial on June 10th, 2005 (ref: 1434).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82127342</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIBH-1434</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, randomized, unblinded trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32721684-a377-4b88-bd42-da9d01d01924">
	  <name>Direccion Medica</name>
	  <address/>
	  <city>Mexico City</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>14000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult hospitalized patients of any age or gender 
2. Diabetes mellitus (World Health Organization criteria) and uncontrolled hyperglycemia on admission (capillary blood glucose &gt;200 mg/dL or HbA1c &gt;7.0)
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Forty five patients on each protocol. Al teast ninety patients overall.</totalTarget>
      <exclusion>1. Good glycemic control on oral medication
2. Refusal to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 Diabetes Mellitus</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Type 2 Diabetes Mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two general wards of a tertiary care hospital were randomly assigned to one of two standardised insulin protocols. 

The two protocols consist of different proportions of intermediate and regular unmodified human insulin. One of the protocols was delivered in 4 daily injections and the other in 3. At initiation total daily insulin dose was calculated with the same guidelines for both protocols, further dose titration was provided according to pre-stablished glycemic goals and individual requirements. 

Training was provieded to the nursing and medical staff and adherence to the protocol guidelines was supervised by the research team.

After inclusion to this study the patient was treated with the protocol assigned to the ward. Capillary Blood Glucose (CBG) was measured 4 times a day. Fasting Venous Blood Glucose (VBG) was measured according to the attending physician decision. All hypoglycemic episodes were registered in one of two categories: 

1. Laboratory hypoglycemia (CBG &lt;60 mg/dL) 
2. Clinical hypoglycemia (Presence of adrenergic or neuroglycopenic symptoms with CBG &gt;60 mg/dL that reverted after the ingestion of food)

Cause of the hypoglycemic episode was tracked and registered.

The patient was followed until discharge or until transfered to other areas such as the intensive care unit.

Glycemic control was compared in both protocols and, in a secondary analysis, the best protocol was compared with historical controls.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>insulin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16820-0</funderId>
      <contactId>Contact54778_16820</contactId>
      <sponsorId>Sponsor53334</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54778_16820">
    <title>Dr</title>
    <forename>Armando</forename>
    <surname>Villegas-Jimenez</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Direccion Medica
Vasco de Quiroga 15
Seccion XVI
Tlalpan</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55 56 55 90 68</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">armandov@quetzal.innsz.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53334">
    <organisation>The National Institute of Medical Sciences and Nutrition (Mexico)</organisation>
    <website>http://www.innsz.mx</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Vasco de Quiroga 15
Seccion XVI
Tlalpan</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55 54 87 09 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">acabral@quetzal.innsz.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416850.e</gridId>
    <rorId>https://ror.org/00xgvev73</rorId>
  </sponsor>
  <funder id="Funder16820-0">
    <name>This trial was funded by an unrestricted grant from institutional research budget of the National Institute of Medical Sciences and Nutrition (Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran). The National Institute of Medical Sciences and Nutrition is a non-profit organization, and its parental organizations are the Mexican Health Ministry (Secretaria de Salud de Mexico) and the Mexican National Autonomous University (Universidad Nacional Autonoma de Mexico). The National Institute of Medical Sciences and Nutrition is a tertiary care academic hospital.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-08-30T00:00:00.000Z">16469166</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Nutrition and wasting in tuberculosis (TB): Can nutritional supplementation in TB patients improve body weight gain, body composition and treatment outcome?</title>
      <scientificTitle/>
      <acronym>TBGIZI ("GIZI" means "nutrition" in Indonesian)</acronym>
      <studyHypothesis>Th hypothesis is that supplementation of TB patients with macro- and micronutrients patients during the first 2 months of treatment increases body weight gain, as compared to TB patients on standard TB treatment. Secondary hypothses include that above supplementation will increase the production of pro-inflammatory cytokines as measured by ex-vivo whole blood stimulation assay and that lean body mass increases more in patients receiving micro- and macronutrient supplementation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body weight gain and body composition between start of TB treatment and end of the active phase of treatment (2 months later)</primaryOutcome>
      <secondaryOutcome>The following will be assessed at baseline and 2 months: 
1. Micronutrient status
2. Production of inflammatory cytokines</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. The Ethical Review Board of Hasan Sadikin University, University of Padjajaran, Bandung, Indonesia, approved in August 2006 
2. The Ethical Advisory Board, Radboud University Nijmegen, The Netherlands, approved on 16 Feb 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16469166</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WV93-411</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Indonesia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f561fe7-ba16-41e6-9fd4-30eb1951ecfa">
	  <name>Dept. of Internal Medicine</name>
	  <address/>
	  <city>Bandung</city>
	  <state/>
	  <country>Indonesia</country>
	  <zip>40161</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
1. Patients with Ziehl-Neelsen (ZN) staining - positive pulmonary TB 
2. Patients starting, or started &lt;2 weeks ago, with the intensive phase of TB treatment 
3. Subject is &gt;18 years of age
4. Willing to participate in the study, and signing the informed consent form</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>No informed consent.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis / nutritional status and wasting / nutrition and public health</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Newly diagnosed TB patients who fullfil the eligiblity criteria will be randomly allocated according to a previously made random list (randomization in blocks of 4) to either standard treatment + nutritional supplementation (75 patients) or standard treatment only (75 patients). Patients allocated to the nutritional supplementation group will receive 3 biscuits per day for 2 months, containg macro- and micronutriets in addition to their standard TB treatment. These 3 biscuits will provide approximately 450 KCal of energy (or approximately 20% of the daily energy requirements), as well as a wide range of minerals and vitamins, in a doses of approximately half the Daily Required Intakes (DRI&#146;s), and NOT containing iron. Patients will be followed up according to standard clinical practice by the health services until the end of the intensive TB drug treatment phase (2 months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16468-0</funderId>
      <contactId>Contact54426_16468</contactId>
      <sponsorId>Sponsor52981</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54426_16468">
    <title>Dr</title>
    <forename>Frank</forename>
    <surname>Wieringa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. of Internal Medicine
Hasan Sadikin Hospital
Jl. Pasir Kaliki 191</address>
      <city>Bandung</city>
      <country>Indonesia</country>
      <zip>40161</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+62 22 2038 986</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wieringa@tiscali.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52981">
    <organisation>NWO/WOTRO - Netherlands Organisation for Scientific Research (The Netherlands) </organisation>
    <website>http://www.nwo.nl/nwohome.nsf/pages/NWOA_6UB9S8</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Anna van Saksenlaan 51   </address>
      <city>The Hague</city>
      <country>Netherlands</country>
      <zip>2593 HW </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 3440763 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">WOTRO@nwo.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420488.2</gridId>
    <rorId>https://ror.org/04jsz6e67</rorId>
  </sponsor>
  <funder id="Funder16468-0">
    <name>NWO/WOTRO - Netherlands Organisation for Scientific Research (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-30T00:00:00.000Z">91251359</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of magnetic resonance in non-invasive pancreatic beta-cell imaging: the relation between pancreatic triglyceride accumulation and beta-cell function in human (pre)diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pancreatic triglyceride accumulation, measured by magnetic resonance spectroscopy, is related to beta-cell function in subjects with Impaired Glucose Tolerance and/or Impaired Fasting Glucose.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Triglyceride content of the human pancreas in vivo assessed using non-invasive 1H-MRS
2. Relation between pancreatic triglyceride accumulation and beta-cell function
3. Relation between triglyceride accumulation in the pancreas and other fat compartments within the abdomen</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee VU University Medical Center 18-12-2006 (ref: 2006/219)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91251359</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006/219 sub1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study.</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="067ddee4-402d-41ac-9e8e-78de8ba9972d">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female subjects (aged 35-70 years) 
2. Impaired Fasting Glucose (IFG; plasma glucose &gt; = 6.1 and &lt; 7.0 mmol/l) and/or 
3. IFG (plasma glucose &gt;= 5.6 and &lt; 7.0 mmol/l) and a family history of Diabetes Mellitus type two (DM2; i.e. first and second degree [i.e. grandparents] relatives) and/or 
4. Impaired Glucose Tolerance (IGT; 2-hour plasma glucose during 75 g Oral Glucose Tolerance Test  [OGTT] 7.8-11.1 mmol/l)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known diabetes
2. History or present liver, exocrine pancreatic or renal disease
3. Drug-/alcohol abuse
4. Acute cardiovascular disease &lt;3 months prior to screening
5. Malignant disease
6. Claustrophobia and metal implants or pacemakers (MRI)
7. Lack of capacity to understand the aim of the research
8. Use of the following: 
8.1.  Glucocorticoids
8.2. Cytostatic drugs
8.3. Thiazolidinediones
8.4. Metformin
8.5. Oral contraceptives
8.6. Fibrates
8.7. Anti epileptic drugs
8.8. Centrally acting drugs for neurologic and/or psychiatric indications</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subjects with impaired glucose tolerance and/or impaired fasting glucose</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Glucose Tolerance , Fasting Glucose</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The following will be performed in each subject: 
1. A modified euglycaemic hyperglycaemic clamp with arginine stimulation (After an euglycaemic clamp [120 minutes, 5 mmol/L], there is an hour rest period followed by a hyperglycaemic clamp [110 minutes, 15 mmol/L with 5 grams arginine stimulation])
2. Magnetic Resonance Imaging (MRI) of the abdominal fat compartments 
3. Proton Magnetic Resonance Spectroscopy (1H-MRS)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16609-0</funderId>
      <contactId>Contact54567_16609</contactId>
      <sponsorId>Sponsor53122</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54567_16609">
    <title>Dr</title>
    <forename>M</forename>
    <surname>Diamant</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Deparment of Endocrinology/ Diabetes Center
De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53122">
    <organisation>VU University Medical Center, Diabetes Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr M Diamant
VU University Medical Center 
Deparment of Endocrinology / Diabetes Center 
De Boelelaan 1117 </address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16609-0">
    <name>Merck Sharp &amp; Dohme B.V. Protocol number: P 2129 V1 (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">58162568</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The surplus value of doppler in haemorrhoid artery ligation procedure</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Standard localised ligations are as feasible as doppler-guided ligations of haemorrhoid arteries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incontinence at four months postoperatively.</primaryOutcome>
      <secondaryOutcome>1. Operative variables
2. Visual Analogue Scale (VAS)-pain scores, analgesics (seven days, month one and four)
3. Cleveland Incontinence Score, Complaints (month one and four)
4. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medisch-Ethische toetsingscommissie) on the 24th of May 2007 (ref: METC number M071729).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58162568</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0161b6f0-62d4-4799-b7f2-af99aef0b66f">
	  <name>Canisius-Wilhelmina Hospital</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 GS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Symptomatic grade II/III/IV haemorrhoids
3. At least one unsuccessful rubber band ligation
4. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>92</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>92</totalTarget>
      <exclusion>1. Previous anal surgery
2. Bleeding disorder</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haemorrhoid arteries</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Artery diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Doppler-guided and standard localised haemorrhoidal artery ligation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16861-0</funderId>
      <contactId>Contact54819_16861</contactId>
      <sponsorId>Sponsor53376</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54819_16861">
    <title>Dr</title>
    <forename>S.</forename>
    <surname>Nienhuijs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Canisius-Wilhelmina Hospital
P.O. Box 9015</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 GS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 365 7657</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.nienhuijs@hccnet.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53376">
    <organisation>Catharina Hospital Eindhoven (The Netherlands)</organisation>
    <website>http://www.catharina-ziekenhuis.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 1350</address>
      <city>Eindhoven</city>
      <country>Netherlands</country>
      <zip>5602 ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413532.2</gridId>
    <rorId>https://ror.org/01qavk531</rorId>
  </sponsor>
  <funder id="Funder16861-0">
    <name>Catharina Hospital Eindhoven (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">87502236</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of SCH 351125 on mononuclear cell trafficking to joints, synovial inflammation and expression of chemokines in subjects with rheumatoid arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>SCH 351125 50 mg twice daily (BID) 2/days is an effective treatment for Rheumatoid Arthritis (RA).

Primary objectives of the study are to determine the effects of SCH 351125 on mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis, and to evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg BID in subjects with rheumatoid arthritis when administered for 28 days.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To determine the effects of SCH 351125, a CCR5 receptor antagonist, on  mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis 
2. To evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg twice-daily in subjects with rheumatoid arthritis when administered for 28 days</primaryOutcome>
      <secondaryOutcome>1. To explore the effects of SCH 351125 on:  
1.1. Synovial inflammation via MRI 
1.2. Chemokine expression and concentrations in the plasma, synovial tissue and synovial fluid (messenger Ribonucleic Acid [mRNA] expression only)
1.3. Mononuclear cell concentrations in the peripheral blood
1.4. Clinical signs and symptoms of rheumatoid arthritis
1.5. To determine the single-dose and multiple dose pharmacokinetic profile of SCH 351125 in subjects with rheumatoid arthritis</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee of the Academic Medical Centre (University of Amsterdam) on the 21st January 2004 (ref: 03/267).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87502236</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P03653</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="19cc24de-e7d6-46b4-bf80-38c48be918af">
	  <name>Academic Medical Centre (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Subjects 18 to 70 years of age, of either sex, and of any race
2. Diagnosis of RA according to the American College of Rheumatology (ACR) criteria, for at least six weeks prior to entry in the study
3. Active RA defined as: 
3.1. Three or more tender joints
3.2. Three or more swollen joints, and 
3.3. At least one of the following three:  
3.3.1. Duration of morning stiffness equal to or greater than 45 minutes 
3.3.2. Erythrocyte sedimentation rate equal to or greater than 28 mm/hour
3.3.3. C-reactive protein equal to or greater than 10 mg/L
4. Functional class I, II or III
5. Subjects must be free of any clinically significant disease (other than rheumatoid arthritis) that would interfere with the study evaluations and/or safety
6. Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules
7. Females must not be breast-feeding, and either be of non-childbearing potential (i.e., sterilised via hysterectomy or bilateral tubal ligation or at least one year postmenopausal) or if of child bearing potential, must be practicing effective double barrier contraceptive methods from at least two weeks prior to day 1 and until 30 days following cessation of dosing
8. Female subjects of childbearing potential must have a negative serum pregnancy test (beta human Chorionic Gonadotropin [beta-hCG]) at screening
9. Males must practice an effective barrier method of contraception from day 1 until 30 days following cessation of dosing
10. A physical examination must be without clinically significant findings with exception of those finding related to rheumatoid arthritis
11. At screening, Electrocardiogram (ECG) conduction intervals must be within the gender specific normal range (i.e., QTc for males less than 430 msec and females less than 450 msec)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Individuals with a history of any significant medical disorder which require a physician's care (excluding rheumatoid arthritis) and would interfere with the study evaluations or compromise subject safety
2. Individuals who have a history of any clinically significant local or systemic infectious disease within four weeks prior to drug administration
3. Any subject with an allergy to gadolinium
4. Any subject with a pacemaker, metal object implanted their body or any other device or condition which may interfere with a subject's safety during the Magnetic Resonance Imaging (MRI) procedure
5. Any subject who has received Disease Modifying Anti-Rheumatic Drug (DMARD) treatment within 30 days prior to enrolment (leflunomide requires a charcoal or cholestyramine washout)
6. Any subject who has received anti-Tumour Necrotising Factor (anti-TNF) therapy (except enteracept) or any biologic therapy within the previous 90 days
7. Any subject whose baseline Disease Activity Score (DAS-28) has significantly changed since screening to indicate unstable disease
8. Any individual who does not comply with the requirement that he should not have used:
8.1. Any drugs (including herbal and mineral supplements or vitamins), other than acetaminophen or an approved stable regimen of low dose prednisone (10 mg/day) and/or Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), for at least two weeks prior to study drug administration
8.2. Alcohol in amounts of greater than 50 grams a day throughout the study
9. Subjects that have been diagnosed with Juvenile RA
10. A history of systemic lupus erythematosus, or signs and symptoms suggesting systemic lupus erythematosus
11. Subjects who are positive for hepatitis B surface antigen, hepatitis C Ribonucleic Acid (RNA) or for Human Immunodeficiency Virus (HIV) antibodies
12. Individuals who have participated in a clinical trial of an investigational drug within 90 days prior to the start of study drug administration, or have received prior treatment with a CCR5 receptor antagonist
13. Individuals with a positive screen for drugs of abuse
14. Individuals who have donated blood (greater than 300 mL) within the preceding 90 days
15. Males who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from study start until 30 days after the last study treatment
16. Females who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from two weeks prior to study start until 30 days after the last study treatment
17. Individuals who have received any vaccinations within 30 days prior to screening
18. Individuals with any clinically significant history of food or drug allergy or allergy to any component of SCH 351125
19. Subjects who are not willing to follow the study restrictions or procedures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects with active Rheumatoid Arthritis (RA) were enrolled in a randomised double-blind, placebo-controlled, parallel-group study exposed  to either SCH 351125 50 mg BID or matched placebo, in a 2:1 ratio, for 28 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>SCH 351125</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16857-0</funderId>
      <contactId>Contact54815_16857</contactId>
      <sponsorId>Sponsor53372</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54815_16857">
    <title>Prof</title>
    <forename>P.P.</forename>
    <surname>Tak</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre (AMC)
Department of Clinical Immunology and Rheumatology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 2171</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.p.tak@amc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53372">
    <organisation>Schering Plough Research Institute (USA)</organisation>
    <website>http://www.schering-plough.com/schering_plough/research/research_institute.jsp</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Schering-Plough Corporation Headquarters
2000 Galloping Hill Road
Kenilworth</address>
      <city>New Jersey</city>
      <country>United States of America</country>
      <zip>07033-0530</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417993.1</gridId>
    <rorId>https://ror.org/02891sr49</rorId>
  </sponsor>
  <funder id="Funder16857-0">
    <name>Schering Plough Research Institute (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-17T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-17T00:00:00.000Z">83770226</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of Spirulina platensis supplementation on general health status of HIV infected patients in Burkina Faso</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Daily Spirulina platensis supplementation can improve clinical, nutritional and immunobiological status of HIV infected patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The impact of active daily supplementation of Spirulina platensis on the clinical, nutritional and immunological status of HIV infected patients will be assessed by the following: 
1. Measurement of CD4, viral load, hematological and biochemical parameters at the start, 6 and 12 months of trial
2. Monthly measurement of anthropometric parameters</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Ethics Committee of Centre Muraz (Institut de Recherche en Sciences de la SantÃ© [IRSS]), approved on 20 December 2005 (ref: 022/2005/CEI-CM)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83770226</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="94467c70-9df4-49f3-a6fa-da5c49dad463">
	  <name>Institut de Recherche en Sciences de la SantÃ©</name>
	  <address/>
	  <city>Bobo-Dioulasso</city>
	  <state/>
	  <country>Burkina Faso</country>
	  <zip>545</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. HIV infected 
2. At least 18 years old 
3. Willing to be followed up for at least 12 months 
4. Informed consent to be provided by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Patients who do not consent to be involved in the trial
2. Under the age of 18 years
3. Patients who are pregnant 
4. Cardiopathy or cancer
5. Currently receiving Spirulina platensis spplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HIV / AIDS</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV / AIDS</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 60 Patients with 200 CD4/Âµl of peripheric blood or lower (patients who are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os (orally) for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Group 2: 60 Patients with 200 &lt; CD4 &lt; 400 (patients who are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Group 3: 60 Patients with CD4 &gt;400 (some of these patients are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Each included patient in the trial will be followed up monthly by a physician. 
Anthropometric parameters of the participants will be measured monthly and their CD4, viral load, hematological and biochemical parameters will be measured semestrially.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Spirulina platensis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16577-0</funderId>
      <contactId>Contact54535_16577</contactId>
      <sponsorId>Sponsor53090</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54535_16577">
    <title>Prof</title>
    <forename>Jean Bosco</forename>
    <surname>Ouedraogo </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institut de Recherche en Sciences de la SantÃ©
Direction RÃ©gionale de l'Ouest
399, Avenue de la LibertÃ©
01 BP 545 Bobo-Dioulasso 01</address>
      <city>Bobo-Dioulasso</city>
      <country>Burkina Faso</country>
      <zip>545</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 20 98 18 80</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbouedraogo.irss@fasonet.bf</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53090">
    <organisation>Ministry of Health of Burkina Faso, Drug Directorate (DGPML)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Projet Spiruline Nayalgue 
S/C Pr Jean-Baptiste Nikiema </address>
      <city>Ouagadougou</city>
      <country>Burkina Faso</country>
      <zip>03 BP 7009 Ouaga</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 50 32 46 60 / 61</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbnikiema@yahoo.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.491199.d</gridId>
    <rorId>https://ror.org/03h83vk17</rorId>
  </sponsor>
  <funder id="Funder16577-0">
    <name>Ministry of Health of Burkina Faso, Drug Directorate (DGPML)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-16T00:00:00.000Z">38727701</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Determinants of thiazide induced hyponatraemia in pre-exposed elderly - a controlled experiment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Thiazide-induced hyponatraemia is caused by impaired free water excretion either due to alterations in the Arginine Dihydrolase (ADH) - Arginine Vasopressin Receptor 2 (AVPR2) - Aquaporin-2 (AQP2) pathway or impaired renal sodium handling.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effect of a single oral dose hydrochloorthiazide 50 mg intake on the serum and urine sodium, serum ADH, prostaglandin E2 and urinary aquaporin-2 excretion in elderly patients (aged 60 - 80 years) with previous thiazide-induced hyponatraemia (sodium less than 125 mmol/l) without another cause for their hyponatraemia and matched controls receiving a thiazide diuretic without hyponatraemia. 

Urinary hydrochlorothiazide concentrations are measured to analyse differences in thiazide metabolism. The response to ADH will be assessed by expression of AVPR2 in a cell-culture and determine its activity by measurement of cyclic Adenosine Monophospahte (cAMP).

Outcomes will be measured at baseline (n = 0) and after 4, 8 and 24 hours.</primaryOutcome>
      <secondaryOutcome>To identify (elderly) patients who are at risk of thiazide induced hyponatraemia.

Outcomes will be measured at baseline (n = 0) and after 4, 8 and 24 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee of the AMC on the 16th August 2007 (ref: MEC 07/059).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38727701</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, controlled experimental study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cf52a276-32d1-4353-8f9b-dda39ffe2677">
	  <name>Academic Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 60 - 80 years
2. Previously admitted with thiazide-induced hyponatraemia
3. Patients must be willing and medically able to discontinue anti-hypertensive therapy six weeks before the study and for the duration of the study
4. Patients must be willing to be admitted for 24 hours and must be medically able to take the study medication
5. Patients must be willing to give informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Other causes for hyponatraemia (e.g. heart failure, pulmonary disease, medication associated with hyponatraemia)
2. Renal dysfunction (estimated clearance less than 50 ml/min according to Cockroft-Gault)
3. Liver cirrhosis
4. Heart failure
5. Medication: antipressiva (Selective Serotonin Reuptake Inhibitors [SSRI&#146;s]), antiepileptica, prednisone, Non-Steroidal Anti-Inflammatory Drugs (NSAID&#146;s), opioids, other diuretics (e.g. lasix, burinex, chloorthalidon, dytac)
6. Allergy for sulphonamide derivates
7. Therapy resistant hypertension (Blood Pressure [BP] greater than 140/90 mmHg while using three or more anti-hypertensive drugs)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Thiazide induced hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All subjects included in this controlled experiment will receive a single dose of Hydrochloorthiazide 50 mg. After that they will be monitored for 24 hours.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydrochloorthiazide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16729-0</funderId>
      <contactId>Contact54687_16729</contactId>
      <sponsorId>Sponsor53243</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54687_16729">
    <title>Dr</title>
    <forename>Nanne </forename>
    <surname>Frenkel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre
Department of Vascular Medicine</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.j.frenkel@amc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53243">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Vascular Medicine
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16729-0">
    <name>Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002997</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">08206786</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>My story as informal care-giver: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The new preventive intervention will lead to a significant decrease in psychological problems and perceived stress, an improvement in the quality of life of the informal care-givers as compared with a waiting list control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Depressive symptoms
2. Perceived stress
3. Quality of life

Outcomes will be measured at:
T0: one week before start of intervention
T1: after three months (directly after intervention)
T2: after six month (three months after intervention)</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (METIGG kamer Noord) on the 23rd January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08206786</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5190312-eef5-4cc5-9fc7-32e717c8ff57">
	  <name>Trimbos-Instituut</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3500 AS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adults above the age of eighteen who provide informal care for a parent and feel they are under stress as a result.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. The parent of the informal care-provider is no longer able to take part in the life review, e.g. because of having severe dementia
2. The health situation of the parent or informal caregiver requires acute assistance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Informal care-givers, prevention, depression, burnout, stress</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Psychological problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The Informal care-givers in Balance course consists of eight two-hour sessions and is designed for adult children who provide structural care for a parent in need of care and are under high perceived stress as a result. At the first three sessions, the participants learn to interview their own parent according to the life review method. Starting at the fourth session of the course, the perspective shifts to the informal care-givers&#146; own life. The informal care-givers focus on the meaning and effects, especially undesirable ones, of the informal care on their lives and on the balance they would like to establish in their lives in accordance with the life review method. The possibilities are addressed for introducing a better balance.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16554-0</funderId>
      <contactId>Contact54512_16554</contactId>
      <sponsorId>Sponsor53067</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54512_16554">
    <title>Dr</title>
    <forename>Ernst</forename>
    <surname>Bohlmeijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Trimbos-Instituut
P.O. Box 725</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3500 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2971100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ebohlmeijer@trimbos.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53067">
    <organisation>Trimbos-Institute - Netherlands Institute of Mental Health and Addiction (The Netherlands)</organisation>
    <website>http://www.trimbos.nl/default37.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 725</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3500 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2971100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@trimbos.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416017.5</gridId>
    <rorId>https://ror.org/02amggm23</rorId>
  </sponsor>
  <funder id="Funder16554-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-05-01T00:00:00.000Z">59798735</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease</title>
      <scientificTitle/>
      <acronym>COXPKPD (COX-2 inhibition monitored by PK11195 in Parkinson's Disease)</acronym>
      <studyHypothesis>Celecoxib inhibits cerebral activated microglia in Parkinson's disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>One baseline and one follow-up Positron Emission Tomography (PET) scan (PK11195) and one Magnetic Resonance Imaging (MRI) scan will be performed to assess the reduction of specific cerebral radiotracer uptake (volume of distribution according to Logan graphical method) after celecoxib.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Review Committee of the University Medical Center Groningen. Approval pending as of 28 February 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59798735</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>16901</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, non-randomised, non-placebo controlled, pilot phase trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cee260f2-c435-4e29-84b5-ee4a168c5a35">
	  <name>University Medical Center Groningen (UMCG)</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Early Parkinson's disease patients
2. Hoehn and Yahr Parkinson's Disease Rating Scale (HY) 1 - 2</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Gastrointestinal diseases</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Parkinson's disease</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Parkinson's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions amended as of 05/09/2007: 
All participants will receive celecoxib oral medication of 100 mg daily for 1 month. 

Interventions provided at time of registration: 
Celecoxib oral medication of 100 mg daily for 1 month.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Celecoxib</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16254-0</funderId>
      <funderId>Funder16254-1</funderId>
      <contactId>Contact54209_16254</contactId>
      <sponsorId>Sponsor52763</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54209_16254">
    <title>Prof</title>
    <forename>Klaus</forename>
    <surname>Leenders</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Groningen (UMCG) 
Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52763">
    <organisation>University Medical Center Groningen (UMCG) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.l.leenders@neuro.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder16254-0">
    <name>University Medical Center Groningen (UMCG) Neurology department deparmental funding (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16254-1">
    <name>Stichting International Parkinson Fonds (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">31186536</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of physiotherapy upon shoulder function following axillary dissection in breast cancer: a pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Physiotherapy is effective in patients with mastectomy and Axillary Lymph Node Dissection (ALND), for shoulder/arm mobility and pain primarily and quality of life secondarily.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Shoulder mobility (flexion [0 - 180Â°], abduction [0 - 180Â°]), measured by use of a digital inclinometer under standardised conditions
2. Pain in the shoulder/arm, measured using the VAS score (zero to ten, zero = no pain, ten = unbearable pain)</primaryOutcome>
      <secondaryOutcome>1. Disabilities in daily life, measured by the DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire (zero to 100, zero = no functional problems, 100 = maximal problems)
2. Oedema (ml), measured in both arms by means of water displacement, grip strength (Kg) of both hands, measured using the hand-held dynamometer and quality of life, as measured by the SIP (Sickness Impact Profile-short version) questionnaire (zero to 68, zero = good health status, 68 = sever physically disabled)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 05/09/2007: The regional medical ethics board approved the study.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31186536</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded  multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4b3f34e6-648f-4059-8e70-d4460a5805e4">
	  <name>University Medical Centre Nijmegen (UMCN)</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18 years of age and older
2. Breast cancer with an ALND
3. A Visual Analogue Scale (VAS)-pain score (zero to ten) of one minimally
4. Moderate shoulder disabilities in daily life (minimal three points on a five points disability score list)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Patients with a previous contra-lateral mastectomy
2. Patients with insufficient knowledge of the Dutch language to fill in the questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients assigned to the treatment group started physiotherapy two weeks following surgery in a private practice of their own choice. The research assistant contacted the physiotherapist who had to comply with the treatment regime and supplied him or her with information regarding the project and treatment guidelines. This information consisted of:
1. A guideline containing advice and exercises for arm/shoulder, posture correction, coordination exercises, exercises for muscular strength and improvement of the general physical condition
2. Exercises to prevent lymph oedema
3. Instruction for scar massage if necessary
4. A registration form to report the content of the treatment sessions and a three-point scale to indicate whether the amount of treatment sessions was sufficient

The total number of treatments was nine (nine being usually covered by the healthcare insurance), once or twice weekly for the first three weeks, thereafter once a fortnight or less. Patients were asked to perform home exercises on a daily basis for approximately ten minutes a day.

Patients assigned to the control group received a leaflet flyer with advice and exercises for the arm/shoulder for the first weeks following surgery and had no further personal contact with a physiotherapist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17760981 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e870b2e2-73b4-4fee-bcb6-40a79ef1a591" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17760981"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16219-0</funderId>
      <contactId>Contact54174_16219</contactId>
      <sponsorId>Sponsor52728</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54174_16219">
    <title>Dr</title>
    <forename>C H G</forename>
    <surname>Beurskens</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Nijmegen (UMCN)
Afd. Fysiotherapie 645 
P.O. Box 9101</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+ 31 (0)24 361 3812</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.beurskens@fysiocss.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52728">
    <organisation>University Medical Centre Nijmegen (UMCN) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Physiotherapy</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10417.33</gridId>
    <rorId>https://ror.org/05wg1m734</rorId>
  </sponsor>
  <funder id="Funder16219-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">59878178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Exploratory randomised double-blind controlled trial of breast milk fortifier with and without long chain polyunsaturated fatty acid (LCPUFA) supplementation on body composition in preterm infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Breast milk fortifier containing LCPUFA has a measurable effect upon body composition at term when compared with non-LCPUFA supplemented fortifier</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body composition at age term-equivalent</primaryOutcome>
      <secondaryOutcome>Growth, metabolic profile, intrahepatocellular lipid content, brain growth and development, neurological examination</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59878178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Germany</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="942a8880-3bc3-4164-8a49-63b35e2db31d">
	  <name>Imperial College London</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SW10 9NH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Infants born at or below 32 weeks gestational age</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>42</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 of whom 42 will be randomised</totalTarget>
      <exclusion>1. Major congenital abnormality

2. Mother does not wish to provide breast milk or to use donor milk
3. Baby requires gastrointestinal surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Preterm infants</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infants will receive maternal +/- donor breast milk; should breast milk fortifier be indicated in accordance with normal clinical practice, infants will be randomised to receive standard fortifier or LCPUFA supplemented fortifier.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13507-0</funderId>
      <contactId>Contact51162_13507</contactId>
      <sponsorId>Sponsor49560</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51162_13507">
    <title>Prof</title>
    <forename>Neena</forename>
    <surname>Modi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Imperial College London
Chelsea &amp; Westminster Hospital
369 Fulham Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW10 9NH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49560">
    <organisation>Milupa GmbH, Numico Research (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bahnstrasse 14-30</address>
      <city>Friedrichsdorf</city>
      <country>Germany</country>
      <zip>61381</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.433367.6</gridId>
    <rorId>https://ror.org/00aj77a24</rorId>
  </sponsor>
  <funder id="Funder13507-0">
    <name>Numico Research Germany</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-03-09T00:00:00.000Z">85109383</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, placebo controlled trial of prednisone in early Henoch Schonlein Purpura</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85109383</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>95/25S(E)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e1a20502-18c2-4945-9185-e78306987ed1">
	  <name>IWK Health Centre</name>
	  <address/>
	  <city>Halifax</city>
	  <state/>
	  <country>Canada</country>
	  <zip>B3J 3G9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Eligible participants were children between the ages of 2 and 15, presenting to the emergency room within 7 days of onset of Henoch Schonlein Purpura.

Children were excluded if:
1. Another explanation for purpura was present
 2. They had a known underlying systemic vasculitis
3. They had been treated with any form of corticosteroids in the preceding month
4. They had a known chronic illness affecting the renal, gastrointestinal or immune systems
5. They had an active infection
6. They were experiencing a life-threatening complication of Henoch Schonlein Purpura</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Henoch Schonlein Purpura</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2>Coagulation defects, purpura and other haemorrhagic conditions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention:
Prednisone 2 mg/kg for 7 days, 75% on days 8 and 9, 50% on days 10 and 11 and 25% on days 12, 13, 14, then stopped.

Control:
Comparison group was an identical appearing placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prednisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15059282 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="810c47c0-3ace-4b5e-bc00-b007a8ffb5a7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-04-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15059282"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder8211-0</funderId>
      <contactId>Contact20642_8211</contactId>
      <sponsorId>Sponsor17386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact20642_8211">
    <title>Dr</title>
    <forename>Adam</forename>
    <surname>Huber</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>IWK Health Centre
5850 University Avenue</address>
      <city>Halifax</city>
      <country>Canada</country>
      <zip>B3J 3G9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 902 470 8827</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">adamtheresa@hfx.eastlink.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor17386">
    <organisation>Children's Hospital of Eastern Ontario Research Institute (CHEORI) (Canada) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>401 Smyth Road
Room 139</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2686</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">brazeau@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder8211-0">
    <name>Children's Hospital of Eastern Ontario Research Institute (CHEORI) (Canada) (ref: 95/25S[E])</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-03-09T00:00:00.000Z">05982584</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Continuous Negative Extrathoracic Pressure in neonatal respiratory failure</title>
      <scientificTitle/>
      <acronym>CNEP</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05982584</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1989-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1993-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9c37377-9386-4d51-8e78-8897f500da81">
	  <name>Academic Department of Paediatrics</name>
	  <address/>
	  <city>Stoke on Trent</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>ST4 6QG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The trial was undertaken in two neonatal intensive care units, Queen Charlotte's and Chelsea Hospital (QCCH) and North Staffordshire Maternity
Hospital (NSMH), between October 1989 and November 1993.
There were 244 patients: birth weight 1.53 Â± 0.69 kg (mean Â± SD), gestational age 30.4 Â± 3.5 weeks, with respiratory failure.
Patients were considered for entry at 2 hours of age if they required
additional inspired oxygen or ventilation to maintain an arterial partial pressure of oxygen (PO2) of â‰¥8 kPa (60 mm Hg: conversion factor 7.5) or
an arterial partial pressure of carbon dioxide (PCO2) of &lt;6.5 kPa at Queen Charlotte's and Chelsea Hospital (QCCH) or 8 kPa at North Staffordshire Maternity Hospital (NSMH). This latter difference was because the two participating units had different practices at the time the trial commenced.
Patients were randomised if, after a second assessment at 4 hours of age, they required â‰¥40% inspired oxygen or ventilation to maintain these blood gas measurements.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>244</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>244</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1989-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1993-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neonatal respiratory failure (respiratory distress syndrome)</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Respiratory failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised at four hours of age to receive either standard neonatal intensive care, or standard care plus continuous negative extrathoracic pressure (CNEP, -4 to -6 cm H2O) applied within a purpose-designed neonatal incubator.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1996 Results article in https://pubmed.ncbi.nlm.nih.gov/8951269 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d1d8356f-eb01-4ceb-a6d5-796cf1668092" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1996-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8951269"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder8212-0</funderId>
      <funderId>Funder8212-1</funderId>
      <funderId>Funder8212-2</funderId>
      <funderId>Funder8212-3</funderId>
      <funderId>Funder8212-4</funderId>
      <funderId>Funder8212-5</funderId>
      <funderId>Funder8212-6</funderId>
      <contactId>Contact21642_8212</contactId>
      <sponsorId>Sponsor18386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact21642_8212">
    <title>Prof</title>
    <forename>David</forename>
    <surname>Southall</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Department of Paediatrics
University Hospital of North Staffordshire</address>
      <city>Stoke on Trent</city>
      <country>United Kingdom</country>
      <zip>ST4 6QG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 552575</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">davids@doctors.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor18386">
    <organisation>University Hospital of North Staffordshire (UK)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Newcastle Road</address>
      <city>Stoke on Trent</city>
      <country>United Kingdom</country>
      <zip>ST4 6QG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 715444</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@uhns.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.100995.4</gridId>
  </sponsor>
  <funder id="Funder8212-0">
    <name>Horner &amp; Wells (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-1">
    <name>Priory Foundation (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-2">
    <name>Dunhill Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-3">
    <name>Moorgate Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-4">
    <name>Little Ones (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-5">
    <name>Queen Charlotte's and Chelsea Hospital (QCCH) (UK) - use of their premises</name>
    <fundRef/>
  </funder>
  <funder id="Funder8212-6">
    <name>North Staffordshire Maternity Hospital (NSMH) (UK)  - use of their premises</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-02-23T00:00:00.000Z">64132371</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Zinc sulfate as an adjunct to methylphenidate for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children: a double blind and randomised trial</title>
      <scientificTitle/>
      <acronym>Zinc ADHD Trial</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64132371</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Roozbeh Trial</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="66299fe5-0d06-4578-b6a9-c790dd1f1615">
	  <name>Roozbeh Psychiatric Hospital</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>13337</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects were 44 outpatient children (26 boys and 18 girls) between the ages of 5 - 11 (mean Â± SD was 7.88 Â± 1.67) who clearly met the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnostic criteria for attention-deficit hyperactivity disorder.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Attention Deficit Hyperactivity Disorder (ADHD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/day (with approximately 15 mg zinc element) (group 1) and methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg) (group 2) for a 6 week double blind clinical trial. The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist at baseline, 14, 28 and 42 days after the medication started.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methylphenidate, zinc sulphate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15070418 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1b727396-1b82-43ff-a5f6-a5fa539d64f3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-04-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15070418"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder7207-0</funderId>
      <contactId>Contact9642_7207</contactId>
      <sponsorId>Sponsor6386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact9642_7207">
    <title>Dr</title>
    <forename>Shahin</forename>
    <surname>Akhondzadeh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roozbeh Psychiatric Hospital
Tehran University of Medical Sciences
South Kargar Street</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.akhond@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor6386">
    <organisation>Tehran University of Medical Sciences (Iran)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>South Kargar Street</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.akhond@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder7207-0">
    <name>Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-02-02T00:00:00.000Z">68653575</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Use of botulinum toxin-A for musculoskeletal pain in patients with whiplash associated disorders</title>
      <scientificTitle/>
      <acronym>Whibotulin</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68653575</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bcb86132-2483-4958-a337-740c7a2209f4">
	  <name>Salamanca, 5</name>
	  <address/>
	  <city>Vigo</city>
	  <state/>
	  <country>Spain</country>
	  <zip>36211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with grade II Whiplash Associated Disorders (WAD) of Quebec Task Force (QTF)-WAD
2. Neck pain secondary to cervical whiplash injury with musculoskeletal signs of greater than three months 
3. Aged greater than 18 years 
4. Lack of response to conventional physical and medical therapy 

Musculoskeletal signs: 
1. Palpable band, spot tenderness, and jump sign in cervical muscles or restricted range of motion in cervical spine 
2. Demonstrated precipitation of neck pain with external pressure over the occipital or cervical region on affected side 
3. Myofascial pain of cervical muscles 
4. Experienced pain on maneuver of stretching 
5. Trigger point with associated referred pain</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Serious somatic or psychiatric illness 
2. Anticoagulation therapy 
3. Myasthenia gravis 
4. Pregnancy or breast-feeding 
5. Abnormal anatomy 
6. Rheumatoid disease or radiculopathy
7. Need for regular analgesic for severe pain</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Whiplash cervical injuries</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Injuries to the neck</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomised, prospective, double blind, placebo-controlled study comparing BotoxÂ® with placebo. 

The study evaluates the efficacy and safety of BotoxÂ® in patients with musculoskeletal pain after whiplash associated disorders.
1. Subjective pain 
2. Assessment of disability due neck pain with the Neck Pain Disability Index 
3. Assessment of Range Of neck Motion (ROM), using CROMÂ® Cervical Range of Motion Instrument
4. Assessment of health status</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Botulinum toxin-A</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in https://pubmed.ncbi.nlm.nih.gov/15018625 Protocol</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a2465e65-067f-4e05-82d6-8ffc089523f4" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-02-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15018625"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6190-0</funderId>
      <contactId>Contact7622_6190</contactId>
      <sponsorId>Sponsor5359</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7622_6190">
    <title>Dr</title>
    <forename>Francisco J</forename>
    <surname>Juan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Salamanca, 5</address>
      <city>Vigo</city>
      <country>Spain</country>
      <zip>36211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 986 413 144</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.juan@arrakis.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5359">
    <organisation>Povisa Medical Center (Povisa Centro Medico) (Spain)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Salamanca, 5</address>
      <city>Vigo</city>
      <country>Spain</country>
      <zip>36211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413176.6</gridId>
    <rorId>https://ror.org/043m85342</rorId>
  </sponsor>
  <funder id="Funder6190-0">
    <name>Povisa Medical Center (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">46272378</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of the effectiveness of critical appraisal skill workshops for health service decision makers in the South and West region</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46272378</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Imp 12-9 Taylor</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8256bd0f-b28b-432f-aa6d-7da00d23c0b3">
	  <name>Dept of Public Health &amp; Epidemiology</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B15 2TT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Health service decision makers public health doctors, general practitioners, and managers in Health Commissions and general practices.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>145</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>145</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Health service decision makers</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants were randomised to attend a workshop immediately (intervention group) or after a delay of 6 months (control group). Baseline measures were documented at entry to the trial. Outcomes were assessed after about 6 months by face-to-face interviews, 6 months after the intervention group have attended a workshop and just before the control group attend a workshop. The timetable for data collection and workshops will be 'blocked' to cover 3 geographic areas.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15585061 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bca61c1c-7fde-452e-bc86-d7a8c88515ff" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-12-07T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15585061"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5806-0</funderId>
      <contactId>Contact7241_5806</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7241_5806">
    <title>Dr</title>
    <forename>Rod</forename>
    <surname>Taylor</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Public Health &amp; Epidemiology
University of Birmingham</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.s.taylor@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5806-0">
    <name>NHS Evaluation of Methods to Promote the Implementation of Research Findings (National Programme) (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">49594804</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of Arthritis Self-Management Programmes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49594804</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="983ab41e-92c0-41c8-ab14-2ec22b26fab6">
	  <name>Centre for Psychosocial Research in Rheumatic Diseases</name>
	  <address/>
	  <city>Coventry</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CV1 5FB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People with arthritis recruited from the community</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>544</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>544</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Musculoskeletal diseases: Arthritis (rheumatoid)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Self-management programme
2. Waiting list control</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2000 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11142075 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d383ea15-9cf2-4fcc-888b-0e1f0788cd9d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2000-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11142075"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5817-0</funderId>
      <contactId>Contact7277_5817</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7277_5817">
    <title>Prof</title>
    <forename>Julie</forename>
    <surname>Barlow</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Psychosocial Research in Rheumatic Diseases
School of Health and Social Sciences
Coventry University
Priory Street</address>
      <city>Coventry</city>
      <country>United Kingdom</country>
      <zip>CV1 5FB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.barlow@coventry.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5817-0">
    <name>NHS Physical and Complex Disabilities National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">46076600</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Patello-femoral joint disease: disability, quadriceps dysfunction and response to physiotherapy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46076600</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8ed80f34-46cb-400f-b424-3334eaa20710">
	  <name>University of Bristol</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS8 2PR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Involving 87 patients with chronic knee pain and radiographic evidence of patello-femoral osteoarthritis, recruited from a large community survey, The Somerset and Avon Survey of Health (SASH).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>87</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>87</totalTarget>
      <exclusion>1. Severe tibio-femoral joint disease
2. No current pain at entry
3. Being treated with physical therapy at entry</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Musculoskeletal diseases: Arthritis (osteo)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 8 weeks intensive physiotherapy with patellar taping
2. Continuing standard care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12784408 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bccec887-f90f-4ba9-a525-675db6bc9cbb" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12784408"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5819-0</funderId>
      <contactId>Contact7292_5819</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7292_5819">
    <title>Prof</title>
    <forename>Paul</forename>
    <surname>Dieppe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Bristol

Canynge Hall

Whiteladies Road</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS8 2PR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 928 7299</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.dieppe@bristol.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5819-0">
    <name>NHS Physical and Complex Disabilities National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-24T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">37846533</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial and cost-effectiveness evaluation of an interactive video system to promote shared decision making in general practice</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine whether a decision aid on benign prostatic hypertrophy influences decision making, health outcomes, and resource use.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patients' and general practitioners' perceptions of who made the decision, decisional conflict scores, treatment choice and prostatectomy rate, American Urological Association symptom scale, costs, anxiety, utility, and general health status.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37846533</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PSI04-13</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92f7f8d6-519a-4a82-95e3-a9883f0b2714">
	  <name>Primary Care and Population Sciences</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>N19 3EU</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men attending participating general practices with a clinical diagnosis of benign prostatic hypertrophy and sufficient command of English to consult without an interpreter
2. Any clinical suggestion of carcinoma of the prostate
3. Chronic retention of urine
4. Recent urinary tract infection
5. Recent acute urinary retention
6. History of prostate surgery
7. Severe visual or hearing impairment, such that the patient could not use the decision aid
8. Severe learning difficulties or mental illness, such that the patient might not be competent to reach an informed decision</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>112</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>112</totalTarget>
      <exclusion>1. Any clinical suggestion of carcinoma of the prostate
2. Chronic retention of urine
3. Recent urinary tract infection
4. Recent acute urinary retention
5. History of prostate surgery
6. Severe visual or hearing impairment, such that the patient could not use the decision aid
7. Severe learning difficulties or mental illness, such that the patient might not be competent to reach an informed decision</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urological and genital diseases: Other urological and genital disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Benign prostatic hypertrophy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with clinical diagnosis of benign prostatic hypertrophy were referred into the study by their General Practitioner (GP). The intervention group received an information package consisting of a session with an evidence based interactive video disc plus printout plus booklet; the control group received normal care only. Data were collected at baseline, three months and nine months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2001 Results article in https://pubmed.ncbi.nlm.nih.gov/11532845/</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="de64937d-c8a2-4f38-b021-babeda06d991" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2001-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11532845/"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5850-0</funderId>
      <contactId>Contact7201_5850</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7201_5850">
    <title>Dr</title>
    <forename>Elizabeth</forename>
    <surname>Murray</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Primary Care and Population Sciences
University College London
Holborn Union Building
Archway Campus</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>N19 3EU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7288 3091</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">elizabeth.murray@pcps.ucl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5850-0">
    <name>NHS Primary and Secondary Care Interface National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-12-22T00:00:00.000Z">08745124</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomised cross-over trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08745124</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>UF 7546</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="17279974-eb57-4325-ad4e-9046ab43fbc4">
	  <name>Centre d'Investigation Clinique - HÃ´pital Saint Eloi</name>
	  <address/>
	  <city>Montpellier</city>
	  <state/>
	  <country>France</country>
	  <zip>34295 cedex 5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy male volunteers aged 20-29 years</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Beta-cell function, insulin sensitivity and glucose effectiveness</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Insulin sensitivity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Single infusion of diazepam (10 mg), clonazepam (1 mg) or placebo just before a frequently sampled intravenous glucose tolerance test.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Diazepam, clonazepam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15102335 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6a2193fd-6dc0-44d4-ae46-7dbcae3a46bd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-03-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15102335"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5739-0</funderId>
      <contactId>Contact7172_5739</contactId>
      <sponsorId>Sponsor5336</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7172_5739">
    <title>Prof</title>
    <forename>Pierre</forename>
    <surname>Petit</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre d'Investigation Clinique - HÃ´pital Saint Eloi 
80 avenue Augustin Fliche</address>
      <city>Montpellier</city>
      <country>France</country>
      <zip>34295 cedex 5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5336">
    <organisation>University Teaching Hospital of Montpellier (CHU de Montpellier) (France)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Direction Recherche et Valorisation - HÃ´pital La ColombiÃ¨re 
39 avenue Charles Flahault</address>
      <city>Montpellier</city>
      <country>France</country>
      <zip>34295 cedex 5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.157868.5</gridId>
    <rorId>https://ror.org/00mthsf17</rorId>
  </sponsor>
  <funder id="Funder5739-0">
    <name>French Health Products Safety Agency (Agence franÃ§aise de sÃ©curitÃ© sanitaire des produits de santÃ© [Afssaps]) (France) - Appel d'offres 1996 de projets de recherche en pharmacologie clinique et thÃ©rapeutique</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-12-10T00:00:00.000Z">76623768</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Metamucil on Bowel Preparation for Colonoscopy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76623768</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0be6655d-8cd1-4d3f-b60a-d91e87adabbf">
	  <name>4646 John R</name>
	  <address/>
	  <city>Detroit</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>48201</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients scheduled for colonoscopy using a standard lavage preparation</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>64</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>64</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bowel Preparation for Colonoscopy</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colonoscopy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomised to 4 days of Metamucil versus Placebo prior to consuming a standard lavage, followed by colonoscopy</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Metamucil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15005812 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0b554e5f-9eb6-44de-aaf5-3bf4a9f9e173" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-02-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15005812"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5734-0</funderId>
      <funderId>Funder5734-1</funderId>
      <contactId>Contact7167_5734</contactId>
      <sponsorId>Sponsor5330</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7167_5734">
    <title>Dr</title>
    <forename>Marc</forename>
    <surname>Basson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>4646 John R</address>
      <city>Detroit</city>
      <country>United States of America</country>
      <zip>48201</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5330">
    <organisation>Procter and Gamble Company (USA) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 8006</address>
      <city>Mason,Ohio</city>
      <country>United States of America</country>
      <zip>45040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418758.7</gridId>
    <rorId>https://ror.org/04dkns738</rorId>
  </sponsor>
  <funder id="Funder5734-0">
    <name>Procter and Gamble Company (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder5734-1">
    <name>Wayne State University (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100006710</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-10-27T00:00:00.000Z">27450856</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of acupuncture with chronic pain caused by osteoarthritis of the knee (gonarthrosis): a multi-centre and randomised controlled clinical trial</title>
      <scientificTitle/>
      <acronym>GERAC-GA</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27450856</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="274a8cdd-5495-451d-8dc5-2c333ca62332">
	  <name>Klinikum der Stadt Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male and female) over 40 with chronic pain (greater than 6 months) due to gonarthrosis (American College of Rheumatology [ACR] criteria)
2. A Kellgren-Lawrence-Score of 2 or 3
3. A Western Ontario and McMaster Universities Arthritis Index (WOMAC) of greater than 3 (scale: 0 - 10)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>900</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>900</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis of the knee (gonarthrosis)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Physiotherapy for all participants, additionally three intervention groups:
A. Standard therapy with diclofenac or rofecoxib
B. Defined specific acupuncture regarding Traditional Chinese Medicine (TCM) (verum acupuncture)
C. Defined unspecific acupuncture (sham acupuncture)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in https://pubmed.ncbi.nlm.nih.gov/15040805 Protocol
2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16818924 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="26924e28-ef58-4b69-8ffd-2bc8500de821" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-03-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15040805"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="eb10d6f5-b942-446d-81a0-7119673e68f3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16818924"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5132-0</funderId>
      <contactId>Contact5559_5132</contactId>
      <sponsorId>Sponsor5242</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5559_5132">
    <title>Prof</title>
    <forename>Hanns-Peter</forename>
    <surname>Scharf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinikum der Stadt Mannheim
Theodor-Kutzer-Ufer</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5242">
    <organisation>Ruhr University Bochum (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department for Medical Information Technology, Biometry and Epidemiology (AMIB)
c/o Prof. Dr. HJ Trampisch  
Overbergstr. 17</address>
      <city>Bochum</city>
      <country>Germany</country>
      <zip>44780</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5570.7</gridId>
    <rorId>https://ror.org/04tsk2644</rorId>
  </sponsor>
  <funder id="Funder5132-0">
    <name>German Health Insurances (AOK, IKK, BKK, Bundesknappschaft, BLK, SKK) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-10-23T00:00:00.000Z">03626626</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase IIa trial of interferon-beta-1a (Avonex) in patients with rheumatoid arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03626626</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="43a8b417-1a76-4299-9c78-683979bf16e9">
	  <name>1000 Welch Road, Suite 203</name>
	  <address/>
	  <city>Palo Alto</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>94304</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Greater than 18 years old who meet the American College of Rheumatology criteria for Rheumatoid Arthritis (RA) 
2. Failed at least one currently available Disease Modifying Anti-Rheumatic Drug (DMARD)
3. Active RA with greater than 6 swollen and 6 tender joints
4. C-Reactive Protein (CRP) exceeding 1.0 mg/dl</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>22</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>22</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis (RA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interferon-beta-1a 30 mcg (or matched placebo) intramuscularly each week for 24 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II/III</phase>
	<drugNames>Interferon-beta-1a (Avonex)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/14979940 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="19e95593-4a5c-49c9-beac-0322876443bf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/14979940"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5717-0</funderId>
      <contactId>Contact7148_5717</contactId>
      <sponsorId>Sponsor5311</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7148_5717">
    <title>Dr</title>
    <forename>Mark</forename>
    <surname>Genovese</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1000 Welch Road, Suite 203</address>
      <city>Palo Alto</city>
      <country>United States of America</country>
      <zip>94304</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5311">
    <organisation>Biogen Idec Inc. (USA)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>14 Cambridge Center</address>
      <city>Cambridge</city>
      <country>United States of America</country>
      <zip>02142</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417832.b</gridId>
    <rorId>https://ror.org/02jqkb192</rorId>
  </sponsor>
  <funder id="Funder5717-0">
    <name>Biogen Idec Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-08-19T00:00:00.000Z">52633712</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized, placebo controlled, trial of preoperative sustained release betamethasone plus non-controlled intraoperative ketorolac or fentanyl on pain after diagnostic laparoscopy or laparoscopic tubal ligation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52633712</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Betamethasone ARF#1212</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="edf30969-e39d-4e66-91a0-16848325c4ef">
	  <name>UT Graduate School of Medicine</name>
	  <address/>
	  <city>Knoxville</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>37920</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients undergoing laparoscopic surgery at University of Tennessee Medical Centre
Knoxville, Tennessee (USA)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>74</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>74</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Sustained release betamethasone versus placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Betamethasone, ketorolac, fentanyl</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12932277 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a52763d4-ed70-40c4-9448-375911d4aac1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-08-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12932277"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5159-0</funderId>
      <contactId>Contact5588_5159</contactId>
      <sponsorId>Sponsor5274</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5588_5159">
    <title>Prof</title>
    <forename>Roger</forename>
    <surname>Carroll</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>UT Graduate School of Medicine
Department of Anesthesiology
1924 Alcoa Highway</address>
      <city>Knoxville</city>
      <country>United States of America</country>
      <zip>37920</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 865 544 9469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rccarrol@mc.utmck.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5274">
    <organisation>University of Tennessee Anesthesiology Research Fund (USA)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University of Tennessee Graduate School of Medicine
Department of Anesthesiology
1924 Alcoa Highway</address>
      <city>Knoxville</city>
      <country>United States of America</country>
      <zip>37920</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 865 544 9220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">prinehar@mc.utmck.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.267305.5</gridId>
    <rorId>https://ror.org/00xzqjh13</rorId>
  </sponsor>
  <funder id="Funder5159-0">
    <name>University of Tennessee Anesthesiology Research Fund (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-08-11T00:00:00.000Z">53821378</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Retreatment of hepatitis C non-responsive to Interferon: a placebo controlled randomised trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux</title>
      <scientificTitle/>
      <acronym>Retreatment of hepatitis C non-responsive to Interferon.</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN53821378</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1992-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e315f1fe-03e5-44f0-8930-f51ffc1959ef">
	  <name>Dr. Molewaterplein 40</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 GD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with chronic hepatitis C and elevated transaminases who did not respond to previous treatment with standard interferon monotherapy.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>117</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>117</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1992-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic hepatitis C</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Hepatitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to:
1. 6 months combination therapy with interferon alpha-2b (3 MU tiw) and ribavirin (1000 - 1200 mg / day)
2. 6 months ribavirin monotherapy (1000 - 1200 mg / day)
3. 6 months ribavirin placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ribavirin monotherapy, Ribavirin and Interferon combination</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12948399 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b82e7712-00d6-449a-abb5-8b2c9bbd3622" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-08-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12948399"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5146-0</funderId>
      <funderId>Funder5146-1</funderId>
      <contactId>Contact5574_5146</contactId>
      <sponsorId>Sponsor5259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5574_5146">
    <title>Prof</title>
    <forename>Solko Walle</forename>
    <surname>Schalm</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dr. Molewaterplein 40</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4633793</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.schalm@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5259">
    <organisation>Schering Plough International (USA)</organisation>
    <website>http://www.schering.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Janice K. Albrecht
Vice President Clinical Research
Hepatology/GI
2000 Galloping Hill Road</address>
      <city>Kenilworth, New Jersey</city>
      <country>United States of America</country>
      <zip>07033-0530</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 908 298 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">janice.albrecht@spcorp.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.417993.1</gridId>
    <rorId>https://ror.org/02891sr49</rorId>
  </sponsor>
  <funder id="Funder5146-0">
    <name>Foundation for Liver Research in Rotterdam (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder5146-1">
    <name>ICN Pharmaceuticals and Schering Plough International provided free drug and placebo and financial support</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-11-14T00:00:00.000Z">18054903</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Time variability of flush-onset and flush tolerabililty in individuals given 500 mg niacin (nicotinic acid): a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18054903</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9a2ce2a5-59e6-4e2c-95c3-b2567319a44b">
	  <name>Director of Research</name>
	  <address/>
	  <city>North York, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M2K 1E2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age range 20 - 60 years
2. Currently enrolled at The Canadian College of Naturopathic Medicine (CCNM)
3. Not currently taking any prescribed medication that influences gastric acid secretion
4. Does not have current or past liver disease (e.g., chronic active hepatitis, cirrhosis, etc)
5. Does not have current or past history of gout or active gout
6. Does not have current or past gastrointestinal disease (e.g., peptic ulcer disease, gastric cancer, etc)
7. Does not have current or past diagnosis of diabetes mellitus
8. Does not have a past episode or history of intolerance to niacin
9. Was able to complete the intake form</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cutaneous reactions (flushing)</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Cutaneous reactions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants divided into two groups:
1. Verum group takes one 500 mg tablet of niacin
2. The control group takes a placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Niacin (nicotinic acid)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in https://pubmed.ncbi.nlm.nih.gov/14614780 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fc02351e-ae1c-4cf7-b9a6-e7597e76d532" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-11-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/14614780"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1457-0</funderId>
      <funderId>Funder1457-1</funderId>
      <contactId>Contact54868_1457</contactId>
      <sponsorId>Sponsor5009</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54868_1457">
    <title>Mr</title>
    <forename>Edward</forename>
    <surname>Mills</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Director of Research
Canadian College of Naturopathic Medicine
1255 Sheppard Ave East</address>
      <city>North York, Ontario</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 498 1255 ext 324</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">emills@ccnm.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5009">
    <organisation>Canadian College of Naturopathic Medicine (Canada) </organisation>
    <website>http://www.ccnm.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1255 Sheppard Ave East</address>
      <city>North York, Ontario</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418588.8</gridId>
    <rorId>https://ror.org/03pjwtr87</rorId>
  </sponsor>
  <funder id="Funder1457-0">
    <name>Canadian College of Naturopathic Medicine (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1457-1">
    <name>Jamieson Laboratories donated the study drug and placebo. They had no role in study design, data analysis, and they have not received the study results.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2002-10-03T00:00:00.000Z">70703138</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of therapy on residual beta cell function in type-1 diabetes mellitus</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Under consideration of baseline data the difference of C-peptide levels between patients under intensive therapy and conventional therapy depends on the willingness of the patients to take part in such a clinical study
2. The failure rate of intensive therapy is less than the rate of conventional therapy</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70703138</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d06a3778-f759-4297-b950-829415dc0cd2">
	  <name>Clinical Research Unit</name>
	  <address/>
	  <city>Giessen, Rodthohl 6</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-35385</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men or women aged 18 - 40 years at diagnosis
2. Established Type-1 Diabetes diagnosed up to three months ago
3. Consent to participate in a diabetes training programme
4. Informed consent before enrolment</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. History of neuropathy, nephropathy, and retinopathy of other than diabetes related origin
2. Negative C-peptide level at diagnosis
3. History of psychiatric disease or drug or alc ohol abuse
4. Treatment with oral antidiabetic medication
5. Subject unlikely to comply with the protocol (e.g. inability or unwillingness to participate adequate training or to complete diaries appropriately) or to understand the nature and the scope of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 1 diabetes mellitus</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Conventional or intensive insulin therapy</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Protocol article in https://pubmed.ncbi.nlm.nih.gov/14667244 Protocol</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0f2fc7fb-4ad3-4e9d-9e22-a62a0a510ac0" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2003-12-10T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/14667244"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1417-0</funderId>
      <contactId>Contact5201_1417</contactId>
      <sponsorId>Sponsor5049</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5201_1417">
    <title>Dr</title>
    <forename>Thomas</forename>
    <surname>Linn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Research Unit
3rd Medical Clinic and Policlinic
Justus Liebig University</address>
      <city>Giessen, Rodthohl 6</city>
      <country>Germany</country>
      <zip>D-35385</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)641 99 42841</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">thomas.linn@innere.med.uni-giessen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5049">
    <organisation>Justus Liebig University (Germany) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Giessen Rodthohl 6</city>
      <country>Germany</country>
      <zip>D-35385</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8664.c</gridId>
    <rorId>https://ror.org/033eqas34</rorId>
  </sponsor>
  <funder id="Funder1417-0">
    <name>Justus Liebig University (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-09-12T00:00:00.000Z">69862441</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A pragmatic randomised trial of exercise training in older people with heart failure</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN69862441</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006/918</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0b48b30e-bb31-4bc3-b75c-b083f665c0b1">
	  <name>Ageing and Health</name>
	  <address/>
	  <city>Dundee</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>DD1 9SY</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Aged 70 years or over with New York Heart Association (NYHA) class II and III chronic heart failure</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>82</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>82</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic stable heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Individualised, graduated exercise training versus usual care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15842989 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d5c276c7-5326-4bf3-9553-0265928cf452" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15842989"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1432-0</funderId>
      <contactId>Contact5381_1432</contactId>
      <sponsorId>Sponsor5112</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5381_1432">
    <title>Professor</title>
    <forename>Marion ET</forename>
    <surname>McMurdo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ageing and Health
Department of Medicine
University of Dundee
Ninewells Hospital</address>
      <city>Dundee</city>
      <country>United Kingdom</country>
      <zip>DD1 9SY</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1382 632436</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.e.t.mcmurdo@dundee.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5112">
    <organisation>The Health Foundation (UK)</organisation>
    <website>http://www.pppfoundation.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>90 Long Acre</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC2E 9RA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7257 8000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@health.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453604.0</gridId>
    <rorId>https://ror.org/02bzj4420</rorId>
  </sponsor>
  <funder id="Funder1432-0">
    <name>The Health Foundation (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-08-29T00:00:00.000Z">32154832</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Water warming garment versus forced air warming system in prevention of intraoperative hypothermia during liver transplantation: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The institutional review board at Vanderbilt University approved the study protocol.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32154832</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="077ce58c-be3c-45d1-8dba-283c3c0049bf">
	  <name>Department of Anesthesiology</name>
	  <address/>
	  <city>Nashville</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>TN 37232-4125</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with liver disease undergoing liver transplantation or liver resection under general anesthesia</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Liver disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Liver disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intraoperative use of either forced-air warmer or water warming garment for maintenance of patient temperature during surgery</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/12441007 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="81a66160-afd1-4397-ab83-40d271883eef" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-11-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12441007"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1430-0</funderId>
      <funderId>Funder1430-1</funderId>
      <contactId>Contact5186_1430</contactId>
      <sponsorId>Sponsor5035</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5186_1430">
    <title>Dr</title>
    <forename>Piotr K I</forename>
    <surname>Janick</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Anesthesiology
Vanderbilt University Medical Center
504 Oxford House
1313 21st Ave S</address>
      <city>Nashville</city>
      <country>United States of America</country>
      <zip>TN 37232-4125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 615 322 3524</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Piotr.janicki@mcmail.vanderbilt.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5035">
    <organisation>Vanderbilt University Medical Center (USA)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Anesthesiology 
504 Oxford House
1313 21st Ave S</address>
      <city>Nashville</city>
      <country>United States of America</country>
      <zip>TN 37232-4125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412807.8</gridId>
    <rorId>https://ror.org/05dq2gs74</rorId>
  </sponsor>
  <funder id="Funder1430-0">
    <name>Vanderbilt University Medical Center (USA) - Department of Anesthesiology</name>
    <fundRef/>
  </funder>
  <funder id="Funder1430-1">
    <name>MTRE Advanced Technologies Ltd (Israel)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-08-28T00:00:00.000Z">84429599</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of a client-administered, lap-top questionnaire for blood-borne diseases in donor populations</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84429599</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a98997df-3c8c-4548-bde8-71480f48120f">
	  <name>Program for Appropriate Technology in Health (PATH)</name>
	  <address/>
	  <city>Seattle</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>WA 98017-5136</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All potential blood donors attending clinics who have the ability to read and understand English</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1239</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1239</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Blood-borne diseases in donor populations</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Blood-borne diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Cross-over of order of questionnaire method: written versus computerised.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/12191432 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a17169f2-b03f-4a26-9142-4e3d91144fce" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-08-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12191432"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1410-0</funderId>
      <contactId>Contact5216_1410</contactId>
      <sponsorId>Sponsor5074</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5216_1410">
    <title>Mr</title>
    <forename>John W.</forename>
    <surname>Sellors</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Program for Appropriate Technology in Health (PATH)
1455 NW Leary Way</address>
      <city>Seattle</city>
      <country>United States of America</country>
      <zip>WA 98017-5136</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 206 285 3500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jsellors@path.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5074">
    <organisation>McMaster University (Canada)</organisation>
    <website>http://www.mcmaster.ca/home.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Hamilton</city>
      <country>Canada</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.25073.33</gridId>
    <rorId>https://ror.org/02fa3aq29</rorId>
  </sponsor>
  <funder id="Funder1410-0">
    <name>Canadian Red Cross Society Research and Development Fund (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2002-08-02T00:00:00.000Z">32042139</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dose-ranging study of SCH34117 in the treatment of patients with seasonal allergic rhinitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32042139</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>C98-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3a735e2e-71ac-4424-aaa1-c5c29a3c30e1">
	  <name>Medical officer</name>
	  <address/>
	  <city>Kenilworth</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>NJ 07033-0530</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects 12 years or older with a two-year documented history of seasonal allergic rhinitis and otherwise in good health</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1026</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1026</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal allergic rhinitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Diseases of upper respiratory tract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomly assigned once-daily (QD) SCH34117 at doses of 2.5, 5, 7.5, 10, or 20 mg versus placebo for two weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>SCH34117</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/12162793 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6d626463-2d5d-4261-83f1-e1cffa6fd943" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-08-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12162793"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1429-0</funderId>
      <contactId>Contact5203_1429</contactId>
      <sponsorId>Sponsor5088</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5203_1429">
    <title>MD</title>
    <forename>Heribert</forename>
    <surname>Staudinger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical officer
Schering-Plough Research Institute (SPRI)
2015 Galloping Hill Road, K-15-4</address>
      <city>Kenilworth</city>
      <country>United States of America</country>
      <zip>NJ 07033-0530</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5088">
    <organisation>Schering-Plough Research Institute (SPRI) (USA) </organisation>
    <website>http://www.schering-plough.com/rd/rd02_research.html</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>2015 Galloping Hill Road, K-15-4</address>
      <city>Kenilworth</city>
      <country>United States of America</country>
      <zip>NJ 07033-0530</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417993.1</gridId>
    <rorId>https://ror.org/02891sr49</rorId>
  </sponsor>
  <funder id="Funder1429-0">
    <name>Schering-Plough Research Institute (SPRI) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-10T00:00:00.000Z">36539116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind, controlled study of corticosteroid injection in plantar fasciitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36539116</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>C0533</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="55c62494-5e34-49fb-a936-9bcf93840b5c">
	  <name>The London Foot Hospital (during the trials conduct)</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W1P 6AY</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Plantar heel pain</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Plantar heel pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Heel pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Steroid injection alone
2. Local anaesthetic injection alone
3. Steroid injection with a tibial nerve block
4. Local anaesthetic injection with atibial nerve block</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Corticosteroid injection</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15847683 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="49fc25bb-54b4-48ba-bc42-eba357c367a4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-04-22T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15847683"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1393-0</funderId>
      <contactId>Contact5076_1393</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5076_1393">
    <title>Dr</title>
    <forename>Fay</forename>
    <surname>Crawford</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The London Foot Hospital (during the trials conduct)
33 Fitzroy Square</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W1P 6AY</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.crawford@dundee.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1393-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-04-12T00:00:00.000Z">87597684</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Preoperative Acute Normovolaemic Haemodilution (ANH) in combination with Hypotensive Epidural Anaesthesia (HEA)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87597684</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5c4cd9b-3d9d-4ada-854b-70e458e96628">
	  <name>Department of Anaesthesia</name>
	  <address/>
	  <city>Aarhus Amtssygehus</city>
	  <state/>
	  <country>Denmark</country>
	  <zip>DK-8000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients scheduled for primary cemented Total Knee Replacement (TKR) surgery</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>28</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>28</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knee arthroplasty surgery</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Knee surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were consecutive and blindly randomised to hypotensive epidural anaesthesia with or without acute normovolaemic haemodilution.

A mean of 877 ml blood was predonated (19.7% of the total blood volume). Blood loss was, except from the intraoperative loss, significantly higher in the ANH group. The total loss was 1306 mL (ANH) versus 1026 mL (non-ANH), P &lt; 0.05. Except from the first hour postoperatively, haematocrit was identical in between groups postoperatively. The amount of blood transfusion was identical 386 ml (ANH) versus 343 ml (non-ANH) (NS). 50% went through surgery without receiving blood (ANH) versus 58% (non-ANH). No renal, neurological or cardiopulmonary complications were registered.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/11960557 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8d5e1325-3137-46e3-bcd0-45071b24373c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-04-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11960557"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1365-0</funderId>
      <contactId>Contact5261_1365</contactId>
      <sponsorId>Sponsor5015</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5261_1365">
    <title>Mr</title>
    <forename>Palle</forename>
    <surname>Juelsgaard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Anaesthesia
Aarhus University Hospital</address>
      <city>Aarhus Amtssygehus</city>
      <country>Denmark</country>
      <zip>DK-8000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+45 89497575</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Palle.Juelsgaard@aas.auh.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5015">
    <organisation>Aarhus University Hospital (Denmark)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Anaesthesia</address>
      <city>Aarhus Amtssygehus</city>
      <country>Denmark</country>
      <zip>DK-8000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.154185.c</gridId>
    <rorId>https://ror.org/040r8fr65</rorId>
  </sponsor>
  <funder id="Funder1365-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-02-27T00:00:00.000Z">58485613</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of metoprolol CR/XL on diabetic postoperative mortality and cardiovascular morbidity: a randomised, double blind, placebo-controlled, multicentre trial</title>
      <scientificTitle/>
      <acronym>DIPOM</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58485613</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Not Applicable</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="76a5974c-afec-4da8-982a-f52d8618fb9d">
	  <name>Copenhagen Trial Unit</name>
	  <address/>
	  <city>Copenhagen Ã˜</city>
	  <state/>
	  <country>Denmark</country>
	  <zip>DK-2100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients 40 years of age with diabetes undergoing noncardiac major (lasting more than 1 hour) surgery</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes mellitus and major surgery</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Diabetic patients undergoing major noncardiac surgery are randomised to 7 days of perioperative beta blocking (Metoprolol CR/XL [SeloZokÂ®] 100 mg daily) versus placebo treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Metoprolol CR/XL</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16793810 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a16c8214-0887-4801-8bc3-59c753224249" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16793810"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1381-0</funderId>
      <funderId>Funder1381-1</funderId>
      <funderId>Funder1381-2</funderId>
      <funderId>Funder1381-3</funderId>
      <funderId>Funder1381-4</funderId>
      <contactId>Contact5012_1381</contactId>
      <sponsorId>Sponsor5034</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5012_1381">
    <title>Dr</title>
    <forename>Anne Benedicte</forename>
    <surname>Juul</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Copenhagen Trial Unit
Centre for Clinical Intervention Research
H:S Rigshospitalet
Dept 7102</address>
      <city>Copenhagen Ã˜</city>
      <country>Denmark</country>
      <zip>DK-2100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+45 3545 7156 or +45 3526 7235</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Anne.j@ctu.rh.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5034">
    <organisation>Copenhagen Trial Unit (Denmark)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Centre for Clinical Intervention Research 
H:S Rigshospitalet
Dept 7102</address>
      <city>Copenhagen Ã˜</city>
      <country>Denmark</country>
      <zip>DK-2100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4973.9</gridId>
    <rorId>https://ror.org/05bpbnx46</rorId>
  </sponsor>
  <funder id="Funder1381-0">
    <name>The Danish Heart Foundation (Denmark) (ref: 01-2-5-51A-22931)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1381-1">
    <name>The Danish Diabetes Foundation (Denmark) (ref: C.1)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1381-2">
    <name>The Copenhagen Hospital Corporation's Research Council (Denmark) (ref: 109/01)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1381-3">
    <name>Programme for Strengthening Regional Collaboration within Medical Health Research (Denmark) (ref: 301-070-5199)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1381-4">
    <name>AstraZeneca (Denmark) (ref: AD-MET-0003)</name>
    <fundRef>http://dx.doi.org/10.13039/100004325</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2002-02-26T00:00:00.000Z">10820810</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of kefir on cholesterol concentrations</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10820810</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="87266c1d-e4b3-4ac9-8f68-ade6af77157c">
	  <name>School of Dietetics and Human Nutrition</name>
	  <address/>
	  <city>Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H9X 3V9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Mild hypercholesterolemics</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>13</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>13</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypercholesterolemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Supplements of kefir or milk.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Kefir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11825344 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d1e1b6d7-eafa-4808-9062-63719902ea4f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11825344"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1359-0</funderId>
      <contactId>Contact5185_1359</contactId>
      <sponsorId>Sponsor5054</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5185_1359">
    <title>Dr</title>
    <forename>Peter JH</forename>
    <surname>Jones</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Dietetics and Human Nutrition
21 111 Lakeshore Road
Ste-Anne-de-Bellevue</address>
      <city>Quebec</city>
      <country>Canada</country>
      <zip>H9X 3V9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 398 7547</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jonesp@macdonald.mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5054">
    <organisation>McGill University (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>845 Sherbrooke Sreet
West Montreal</address>
      <city>Quebec</city>
      <country>Canada</country>
      <zip>H3A 2T5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.14709.3b</gridId>
    <rorId>https://ror.org/01pxwe438</rorId>
  </sponsor>
  <funder id="Funder1359-0">
    <name>Liberty Co. (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-02-26T00:00:00.000Z">85429598</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85429598</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="52bcc8ed-7a28-40de-b944-c5829bc38310">
	  <name>George Washington University</name>
	  <address/>
	  <city>Washington DC</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>20037</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women with osteopenia
2. Not taking oestrogen
3. Selective oestrogen receptor modulators
4. Bisphosphonates
5. Calcitonin
6. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Female</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteopenia</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Bone density disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Placebo once a day, at bedtime (qhs)
2. Simvastatin 20 mg qhs
3. Simvastatin 40 mg qhs</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Simvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/11879528 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2f1a938b-ba02-41c4-8374-d7580eb87361" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11879528"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1360-0</funderId>
      <contactId>Contact5118_1360</contactId>
      <sponsorId>Sponsor5042</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5118_1360">
    <title>Dr</title>
    <forename>Judith</forename>
    <surname>Hsia</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>George Washington University
2150 Pennsylvania Ave NW</address>
      <city>Washington DC</city>
      <country>United States of America</country>
      <zip>20037</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 202 004 5461</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">domjah@gwumc.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5042">
    <organisation>George Washington University (USA)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>2150 Pennsylvania Ave NW</address>
      <city>Washington DC</city>
      <country>United States of America</country>
      <zip> 20037</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.253615.6</gridId>
    <rorId>https://ror.org/00y4zzh67</rorId>
  </sponsor>
  <funder id="Funder1360-0">
    <name>Merck &amp; Co. Inc. (USA) - unrestricted grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-02-26T00:00:00.000Z">47364493</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Tidal Breathing Flow-Volume (TBFV) loops in bronchiolitis in infancy: the effect of albuterol</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the effect of nebulized albuterol on tidal breathing flow-volume loops in infants with bronchiolitis due to Respiratory Syncytial Virus (RSV).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47364493</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="abc253d7-7218-413f-ae97-281453e0b8e2">
	  <name>Division of Critical Care Medicine</name>
	  <address/>
	  <city>Miami</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>FL 33155</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>One month to one year infants with Respiratory Syncytial Virus (RSV) positive bronchiolitis</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory Syncytial Virus (RSV) bronchiolitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Bronchiolitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Compared the effect of nebulized albuterol versus nebulized saline on various parameters of tidal breathing flow-volume loops</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Albuterol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/11983043 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ee88e103-4445-4dcb-a724-421b27ed8ba0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11983043"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1380-0</funderId>
      <contactId>Contact5016_1380</contactId>
      <sponsorId>Sponsor5064</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5016_1380">
    <title>Dr</title>
    <forename>Balagangadhar R</forename>
    <surname>Totapally</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Critical Care Medicine
Miami Children's Hospital
3100 SW 62nd Avenue</address>
      <city>Miami</city>
      <country>United States of America</country>
      <zip>FL 33155</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bala.totapally@mch.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5064">
    <organisation>Hurley Medical Center (USA)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>One Hurley Plaza</address>
      <city>Flint</city>
      <country>United States of America</country>
      <zip>MI 48503</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413659.c</gridId>
    <rorId>https://ror.org/034npj057</rorId>
  </sponsor>
  <funder id="Funder1380-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-02-15T00:00:00.000Z">98608690</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: a phase II double-blind randomised placebo-controlled trial</title>
      <scientificTitle/>
      <acronym>PISA</acronym>
      <studyHypothesis>To study the effect of high-dose ibuprofen and to confirm the previously observed reducing effect of high-dose paracetamol on body temperature, and to study their safety in normothermic and subfebrile patients with acute ischaemic stroke.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body temperature at 24 hours from start of treatment.</primaryOutcome>
      <secondaryOutcome>1. Change in baseline temperature at 1 and 5 days from start of treatment
2. Time with elevated body temperature (greater than 37.0Â°C) (area under the curve) during the first 24 hours and the first five days

Tertiary outcomes:
Functional outcome at one month, as determined by the scores on the modified Rankin Scale (mRS) and Barthel Index (BI).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The medical ethics committees of the three hospitals have approved this protocol.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98608690</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="25bcdb16-da39-4d83-aa8e-ca87c4cee894">
	  <name>Dept of Neurology</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. An acute ischaemic anterior circulation stroke
2. A body temperature greater than 36.0Â°C or less than 39.0Â°C
3. A CT scan that is compatible with acute ischaemic stroke
4. A focal deficit without rapid improvement
5. A possibility to start treatment within 24 hours after stroke onset</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>75</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>75</totalTarget>
      <exclusion>1. Severe aphasia, defined as an aphasia score of 2 or 3 on the National Institutes of Health Stroke Scale (NIHSS)
2. Treatment with an non-Steroidal Anti-Inflammatory Drug (NSAID) deemed necessary
3. Hypersensitivity to ibuprofen or paracetamol
4. (Chronic) liver failure or cirrhosis
5. (Chronic) renal failure
6. History of alcohol abuse
7. Active gastric ulcer disease or a history of peptic ulceration or gastro-intestinal haemorrhage in the preceding year
8. Colitis ulcerosa
9. Pregnancy
10. Use of corticosteroids
11. A severe concomitant medical condition that could affect the assessment of the effect of the study medication on temperature
12. Residual neurological impairment resulting from a previous stroke that may hamper the assessment of functional outcome
13. Death appearing imminent
14. No informed consent given</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cerebrovascular diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Paracetamol 6 g daily, for 5 days
2. Ibuprofen 2.4 g daily, for 5 days
3. Placebo for 5 days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Paracetamol (acetaminophen), ibuprofen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Protocol article in https://pubmed.ncbi.nlm.nih.gov/11918829 Protocol
2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12657165 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="594ff7b5-c154-4311-874b-5bff10ecf8d6" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2002-03-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11918829"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="ca57cae4-7560-416e-8ce9-21db865e67d9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-02-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12657165"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1339-0</funderId>
      <contactId>Contact5051_1339</contactId>
      <sponsorId>Sponsor5018</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5051_1339">
    <title>Dr</title>
    <forename>Diederik WJ</forename>
    <surname>Dippel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Neurology
University Hospital Rotterdam
PO Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4639222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dippel@neuro.fgg.eur.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5018">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder1339-0">
    <name>Rotterdam Neurovascular Research Foundation (Stichting Neurovasculair Onderzoek Rotterdam) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-01-31T00:00:00.000Z">99609795</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to explore attitudes to routine scale and polish and compare manual versus ultrasonic scaling</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99609795</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="da4ff6c3-d072-4693-bcb3-461468815b99">
	  <name>Dental Health Services Research Unit</name>
	  <address/>
	  <city>Dundee</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>DD1 4HR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Dentist recruitment:
All dental vocational trainees and general dental professional trainees in Aberdeen, Dundee, and Perth were eligible.

Patient recruitment:
The patient, attending for routine check-up appointment, should be:
1. Adult
2. Dentate
3. Generally fit and well
4. Not fitted with a pacemaker
5. Agreeable to receiving a scale and polish at that visit

Consecutive patients, who met the inclusion criteria, were to be invited to participate in the study up to a limit of 16 per dentist.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Routine dental scale and polish</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2>Routine dental scale and polish</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Normal routine scaling by one of:
1. Manual
2. Ultrasonic application combined with polishing</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Abstract results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15975140</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="733b66f8-6309-4b6d-a12d-159ee3663288" outputType="abstract" artefactType="ExternalLink" dateCreated="2005-06-23T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15975140"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1350-0</funderId>
      <funderId>Funder1350-1</funderId>
      <contactId>Contact5110_1350</contactId>
      <sponsorId>Sponsor53431</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5110_1350">
    <title>Dr</title>
    <forename>Jan E.</forename>
    <surname>Clarkson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dental Health Services Research Unit
Dundee Dental Hospital and School
Park Place</address>
      <city>Dundee</city>
      <country>United Kingdom</country>
      <zip>DD1 4HR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1382 425751</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.e.clarkson@dundee.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53431">
    <organisation>Scottish Council for Postgraduate Dental and Medical Education (UK)</organisation>
    <website>http://scpmde-edu.dundee.ac.uk/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>c/o Dundee Dental Hospital and School
Park Place</address>
      <city>Dundee</city>
      <country>United Kingdom</country>
      <zip>DD1 4HR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.451102.3</gridId>
    <rorId>https://ror.org/011ye7p58</rorId>
  </sponsor>
  <funder id="Funder1350-0">
    <name>Scottish Council for Postgraduate Dental and Medical Education (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1350-1">
    <name>Scottish Executive's Chief Scientist Office (UK) - via Dental Health Services Research Unit</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-01-15T00:00:00.000Z">39974945</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Differential response to right unilateral electroconvulsive therapy (ECT) in depressed patients: impact of comorbidity and severity of illness</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN39974945</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="641ef5f3-21b5-4c99-9a32-69dd039b420e">
	  <name>National Public Health Institute</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>00300</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with a current major depressive episode</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depressive episode</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Right unilateral electroconvulsive therapy dosed at 2.5 or 5 times the initial seizure threshold. Planned study population (n = 40; Group 1, n = 16; Group 2, n = 24), together with inclusion/exclusion criteria. 

Group 1 patients had major depression (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV]) with severity of the major depressive episode greater than 16 scores on 17-item Hamilton Rating Scale for Depression. Group 2 patients had a less severe major depressive episode or some comorbid condition.  

Main comparative analyses between primary outcome measures were completed on an intention-to-treat basis. Randomisation by computer using a block with six patients per block. Assignment was concealed until administration of the first randomised treatment. All evaluators (the attending physicians and the raters) and the patients were blinded to the assignment.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/11846888 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b27142bf-bdb5-4196-b072-0057e4b06b1d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11846888"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1330-0</funderId>
      <contactId>Contact5142_1330</contactId>
      <sponsorId>Sponsor5036</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5142_1330">
    <title>Dr</title>
    <forename>Kimmo</forename>
    <surname>Kuoppasalmi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>National Public Health Institute
Mannerheimintie 166</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>00300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+358 (0)9 47448701</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kimmo.kuoppasalmi@ktl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5036">
    <organisation>Helsinki University Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Psychiatry</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.15485.3d</gridId>
    <rorId>https://ror.org/02e8hzf44</rorId>
  </sponsor>
  <funder id="Funder1330-0">
    <name>The Foundation for Psychiatric Research (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-01-15T00:00:00.000Z">70707830</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Norepinephrine-evoked pain in fibromyalgia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70707830</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ede8ecef-3713-45e1-a53d-6f3c4a2a2dbc">
	  <name>Chief Rheumatology Department</name>
	  <address/>
	  <city>Mexico DF</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>14080</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 20 patients with fibromyalgia
2. 20 patients with rheumatoid arthritis
3. 20 normal controls</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fibromyalgia</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Soft tissue disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Subcutaneous injection of 10 micrograms of norepinephrine diluted in 0.1 ml normal saline solution
2. Subcutaneous injection of 0.1 ml normal saline</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Norepinephrine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/11860612 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="10b7700b-cfe8-4c92-98bb-ebce506232d1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11860612"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1349-0</funderId>
      <contactId>Contact5130_1349</contactId>
      <sponsorId>Sponsor5077</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5130_1349">
    <title>Dr</title>
    <forename>Manuel</forename>
    <surname>MartÃ­nez-LavÃ­n</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Chief Rheumatology Department
Instituto Nacional de Cardiologia Ignacio Chavez
Juan Badiano 1</address>
      <city>Mexico DF</city>
      <country>Mexico</country>
      <zip>14080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 (01)55 732911</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mmlavin@infosel.net.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5077">
    <organisation>Ignacio Chavez National Institute of Cardiology (Instituto Nacional de Cardiologia Ignacio Chavez) (Mexico) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Juan Badiano 1</address>
      <city>Mexico DF</city>
      <country>Mexico</country>
      <zip>14080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419172.8</gridId>
    <rorId>https://ror.org/046e90j34</rorId>
  </sponsor>
  <funder id="Funder1349-0">
    <name>Ignacio Chavez National Institute of Cardiology (Instituto Nacional de Cardiologia Ignacio Chavez) (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>